Mike Frodsham MSc

Dr. Mike Frodsham applies more than 22 years of product development experience to his role as CTO at SGS Quay Pharma where he provides technical oversight of development projects and manufacturing operations. Dr. Frodsham has been involved in more than 300 different development projects, involving a wide range of non-sterile dosage forms including solid dose, liquid, and topical products.

The breadth of Dr. Frodsham’s experience ranges from small molecule developments to the development of products containing live biotherapeutics and antibodies for targeted oral delivery, as well as supporting IMPD/IND submissions. He is named as an inventor of a range of patents, covering various products, including pediatric oral liquids, targeted delivery of polypeptides, and the use of penetration enhancers to improve buccal absorption.

Dr. Frodsham earned a Ph.D. in pharmaceutical sciences from Liverpool John Moores University where his research focused on the conversion of lipid liquid systems into solid dosage forms. He also earned a Master of Science degree in Industrial Pharmaceutical Sciences from the University of Manchester.